Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019

JAMA Netw Open. 2022 Mar 1;5(3):e221117. doi: 10.1001/jamanetworkopen.2022.1117.


This cross-sectional study examines utilization trends for filgrastim and infliximab products and their biosimilars to understand whether biosimilars are associated with reduced spending in Medicare Part D.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Biosimilar Pharmaceuticals* / therapeutic use
  • Filgrastim / therapeutic use
  • Humans
  • Infliximab / therapeutic use
  • Medicare Part D*
  • United States


  • Biosimilar Pharmaceuticals
  • Infliximab
  • Filgrastim